The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells
about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingA first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesTherapeutic targeting of replicative immortalityDevelopment of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent KinasesTargeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma CellsThe impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines.A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaTargeting protein kinases to reverse multidrug resistance in sarcoma.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.Inflammatory stress and sarcomagenesis: a vicious interplay.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.Transcription inhibition as a therapeutic target for cancerTargeted therapies for bone sarcomas.Dinaciclib for the treatment of breast cancer.The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.p27Kip1 inhibits the cell cycle through non-canonical G1/S phase-specific gatekeeper mechanism.Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study.Bone sarcomas: from biology to targeted therapies.MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways
P2860
Q21133611-12C8EDA8-6696-494E-B26B-865FEA0D953CQ21245492-70803C17-4921-4CB3-A826-18AB36E5AAAFQ27027457-16D86A56-5B4D-49E9-B4B0-8F2328C4C3F9Q27677453-BF269A8B-B967-46F2-95CC-F59F33518B67Q28554501-D144149B-F57B-44B9-AC0D-96D276B2B23CQ34195072-CF77B865-ECBC-4D88-9F1B-74C2BB433FA8Q34301314-2B3CF66E-79EB-4799-8D06-CF4FDF224872Q34335802-03210ED0-F52A-4A41-BD14-839C062CE8A8Q35550068-6C8AFF04-5761-465F-B7C7-F271C62C7211Q35846538-752801E6-865E-4B8A-A884-2AF3FB1DAFF0Q36020882-3B9179C4-EF3E-4E4F-A04C-F4823C01679AQ36022718-FBE3D963-2FC9-4DF9-AA26-BFF2E0CC149EQ36282782-8602EB07-1903-459B-8ED0-3FC245641595Q36316518-9A94E9F1-B3FE-42E6-BF17-52E9CD607010Q36527950-09C5E7C9-5487-448D-9488-C741010F157AQ36888962-C52C004D-3BBC-4EB0-B4E7-C1B83DC14E2CQ37199802-9F0A00EB-B802-4A38-834E-E4EF688A14B6Q37378867-26B9E903-D214-4B2C-9635-A57D7ECCD662Q37948079-5500628A-6F00-41EE-BA4E-193B665E128CQ38132245-6B485651-E877-4960-A83F-20EDC5516F92Q38161381-62A520C0-D679-45E0-9E65-8B56B665898EQ38178277-7FBCEEBA-2CEA-43B2-8668-70A5D556C116Q38238282-35882CBC-8DF2-44B9-A124-8A5633815531Q38669852-ADC72386-8DE7-49D5-9AA4-27A23BE94BA1Q38755091-2777D13A-C748-44E3-B66F-89001DA82336Q38809578-2CF47B1A-3086-43F1-9F1E-04D86DCB8956Q40041197-76E4702E-EF10-41A2-A642-528281990D16Q41047795-7635CE91-5060-4993-8D4F-F9BB1AD02988Q41923624-CE2F5138-EAFD-4933-B109-9CF34FD4D954Q42748194-636F723E-4D5F-4B48-B619-C58FD06F02B2Q47294507-44A783FA-A59B-4C84-AB25-A4CC0CDF75F6Q48274640-B9D16B21-40AE-4460-8359-BB447C6C5A2BQ50031768-232C4134-3FE1-43D1-AACC-AAE07CB3CB34Q54322737-B50B135E-2D93-48C0-8492-EEE035368CC1Q54977960-1ED76F37-2AAF-4571-A86F-B171935AA643Q58572387-AE3855F5-1B3C-41EA-A18B-DC99179DBBB9
P2860
The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The cyclin-dependent kinase in ...... poptosis of osteosarcoma cells
@ast
The cyclin-dependent kinase in ...... poptosis of osteosarcoma cells
@en
The cyclin-dependent kinase inhibitor SCH 727965
@nl
type
label
The cyclin-dependent kinase in ...... poptosis of osteosarcoma cells
@ast
The cyclin-dependent kinase in ...... poptosis of osteosarcoma cells
@en
The cyclin-dependent kinase inhibitor SCH 727965
@nl
prefLabel
The cyclin-dependent kinase in ...... poptosis of osteosarcoma cells
@ast
The cyclin-dependent kinase in ...... poptosis of osteosarcoma cells
@en
The cyclin-dependent kinase inhibitor SCH 727965
@nl
P2093
P2860
P1476
The cyclin-dependent kinase in ...... poptosis of osteosarcoma cells
@en
P2093
Jennifer Gemmer
Marilyn M Bui
Soner Altiok
W Jackson Pledger
P2860
P304
P356
10.1158/1535-7163.MCT-11-0167
P50
P577
2011-04-13T00:00:00Z